|
Volumn 55, Issue 4, 2011, Pages 933-935
|
Oral combination therapy: Future hepatitis C virus treatment?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BOCEPREVIR;
DANOPREVIR;
MERICITABINE;
PEGINTERFERON;
PLACEBO;
RIBAVIRIN;
TELAPREVIR;
VIRUS RNA;
ANTIVIRAL ACTIVITY;
AUSTRALIA;
DECOMPENSATED LIVER CIRRHOSIS;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
GENOTYPE;
HEMOGLOBINOPATHY;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
LABORATORY TEST;
NEW ZEALAND;
NONHUMAN;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
SIDE EFFECT;
TREATMENT DURATION;
UNSPECIFIED SIDE EFFECT;
|
EID: 80052943313
PISSN: 01688278
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jhep.2011.04.018 Document Type: Note |
Times cited : (4)
|
References (10)
|